ACIU — AC Immune SA Share Price
0.000.00%
Last trade - 00:00- $234.11m
- $124.71m
- CH₣14.80m
- 36
- 22
- 66
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.33 | ||
| Price to Tang. Book | 1.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 14.39 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.69% | ||
| Return on Equity | -32.9% | ||
| Operating Margin | -362.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CH₣m | 110.46 | 15.43 | n/a | 3.94 | 14.8 | 8.49 | 62.53 | 15.52% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The Company's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. It has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.
Directors
- Douglas Williams NEC (62)
- Andrea Pfeifer CEO (63)
- Joerg Hornstein CFO (43)
- Piergiorgio Donati COO (50)
- Jean-Fabien Monin CAD (50)
- Marie Kosco-Vilbois CSO (63)
- Johannes Streffer OTH (52)
- Monika Butler DRC (60)
- Monica Shaw DRC
- Thomas Graney NID (56)
- Carl June NID (67)
- Werner Lanthaler NID (52)
- Roy Twyman NID (64)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 13th, 2003
- Public Since
- September 23rd, 2016
- No. of Shareholders
- 250
- No. of Employees
- 133
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 99,197,829
- Address
- EPFL Innovation Park, Building B, LAUSANNE, 1015
- Web
- https://www.acimmune.com/
- Phone
- +41 213459121
- Auditors
- PricewaterhouseCoopers SA
Upcoming Events for ACIU
AC Immune SA Annual Shareholders Meeting
Q2 2024 AC Immune SA Earnings Release
Similar to ACIU
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
Adicet Bio
NASDAQ Global Market
FAQ
What is the AC Immune SA share price?
As of Today at 19:00 UTC, shares in AC Immune SA are trading at $2.36. This share price information is delayed by 15 minutes.
How has the AC Immune SA share price performed this year?
Shares in AC Immune SA last closed at $2.36 and the price had moved by +8.76% over the past 365 days. In terms of relative price strength the AC Immune SA share price has underperformed the S&P500 Index by -9.5% over the past year.
What are the analyst and broker recommendations for AC Immune SA?
The overall consensus recommendation for AC Immune SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the AC Immune SA dividend yield?
AC Immune SA does not currently pay a dividend.
Does AC Immune SA pay a dividend?
AC Immune SA does not currently pay a dividend.
When does AC Immune SA next pay dividends?
AC Immune SA does not currently pay a dividend.
How do I buy AC Immune SA shares?
To buy shares in AC Immune SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AC Immune SA?
As of the previous close price of $2.36, shares in AC Immune SA had a market capitalisation of $234.11m.
Where are AC Immune SA shares listed?
Here are the trading details for AC Immune SA:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ACIU
What kind of share is AC Immune SA?
Based on an overall assessment of its quality, value and momentum AC Immune SA is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AC Immune SA share price forecast for 2024?
The analyst consensus target price for shares in AC Immune SA is $10.51. That is 345.15% above the last closing price of $2.36.
Analysts covering AC Immune SA currently have a consensus Earnings Per Share (EPS) forecast of -CH₣0.67 for the next financial year.
What is the trend in the AC Immune SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AC Immune SA. Over the past six months, its share price has underperformed the S&P500 Index by -18.55%.
As of the last closing price of $2.36, shares in AC Immune SA were trading -27.03% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AC Immune SA PE Ratio?
The AC Immune SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AC Immune SA?
AC Immune SA's management team is headed by:
- Douglas Williams - NEC
- Andrea Pfeifer - CEO
- Joerg Hornstein - CFO
- Piergiorgio Donati - COO
- Jean-Fabien Monin - CAD
- Marie Kosco-Vilbois - CSO
- Johannes Streffer - OTH
- Monika Butler - DRC
- Monica Shaw - DRC
- Thomas Graney - NID
- Carl June - NID
- Werner Lanthaler - NID
- Roy Twyman - NID